In its report, Deutsche Bank lowered its profit forecast for China Traditional Chinese Medicine (00570.HK) from 2024 to 2030 by 10% to 14%, considering the monthly trend in the wake of the previous half-year's procurement price reduction. The reason is that the sales and gross margin forecast for the formula granules have been reduced. The target price has been lowered from HK$5.4 to HK$4.9. It is rated as "shareholding".
《大行》大摩降中國中藥(00570.HK)目標價至4.9元 下調盈利預測
Dah Sing lowers target price of Trad Chi Med (00570.HK) to 4.9 yuan and adjusts profit forecast downwards.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.